文献
J-GLOBAL ID:202102229133868248
整理番号:21A0286127
COPD患者におけるナバフェンテロール(AZD8871):この新規,吸入,長時間作用,二重薬理学気管支拡張薬単回投与の安全性および薬力学を評価する無作為化二重盲検第I相試験【JST・京大機械翻訳】
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
著者 (10件):
Singh Dave
(The Medicines Evaluation Unit, Centre for Respiratory and Allergy Medicine, University of Manchester, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK)
,
Balaguer Victor
(Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain)
,
Astbury Carol
(Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain)
,
Waehlby-Hamren Ulrika
(Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden)
,
Jimenez Eulalia
(Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, Spain)
,
Seoane Beatriz
(Biometrics and Information Sciences, Late-Stage Development, BioPharmaceuticals R&D, Barcelona, Spain)
,
Villarroel Cristina
(Late-Stage Development, BioPharmaceuticals R&D; AstraZeneca, Barcelona, Spain)
,
Lei Alejhandra
(Patient Safety RIA, Chief Medical Office, R&D, AstraZeneca, Barcelona, Spain)
,
Aggarwal Ajay
(Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Boston, USA)
,
Psallidas Ioannis
(Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden)
資料名:
Respiratory Research (Web)
(Respiratory Research (Web))
巻:
21
号:
1
ページ:
1-11
発行年:
2020年
JST資料番号:
U7545A
ISSN:
1465-993X
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
イギリス (GBR)
言語:
英語 (EN)